WorldVentures Celebrates Miami, Announces Technology Innovation Updates and Gives Back at Local Boys & Girls Club

WorldVentures Celebrates Miami, Announces Technology Innovation Updates and Gives Back at Local Boys & Girls Club

July 16–Aug. 26 the first 1,000 qualified Representatives will earn the right to purchase the new SmartCard being Developed by NXt-ID  (NASDAQ: $NXTD)

PLANO, Texas - July 18, 2016 (Investorideas.com Newswire) During the weekend, more than 17,000 WorldVentures Independent Representatives from around the country converged on Miami, Fla. for its U.S. sales training event, held at the American Airlines area.

During the training the company announced the This Is Next promotion for its new SmartCard in development. Between July 16–Aug. 26 the first 1,000 qualified Representatives will earn the right to purchase the new SmartCard to be used during the beta testing period targeted for end of Q4.

The technologically innovative SmartCard being designed and produced exclusively for WorldVentures with NXT-ID, Inc. (NASDAQ: NXTD) is a unique card that serves to securely store credit and loyalty cards. Among other features, the SmartCard seamlessly integrates with the DreamTrips™ mobile app to wirelessly check in and earn loyalty points towards DreamTrips vacations from participating restaurants. The strategic alliance was announced in a news release on Jan. 4 and first introduced to the WorldVentures Independent Representatives at the annual UNITED conference Jan. 2016.

"In this high-tech, hyper-connected world, we are enabling people to use technology in a more powerful and compelling way," said Wayne Nugent, World Ventures Founder and Chief Visionary Officer. "And our Independent Representatives will be able to bring this exciting new innovation to travelers all over the world, making their experiences richer, safer, and more engaging and rewarding."

And in the spirit of the WorldVentures Foundation "Heart to Serve", WorldVentures Independent Representatives kicked off the weekend by coming together on the morning of Friday, Jul. 15 for the traditional pre-event Volunteer Day. A group of 100 volunteers provided a field day for the children at the Kendall Boys & Girls Club in Miami. Being on summer break, the kids were able to participate in a fun-filled morning of hula hoop contests, egg tosses, 3-legged races and other games.

"There was so much enthusiasm from our Reps to really make a difference in the lives of kids in Miami," said WorldVentures Foundation Executive Director Gwyneth Lloyd.

Read this release in full at http://www.investorideas.com/CO/NXT/news/2016/07181.asp

About WorldVentures

WorldVentures Marketing, LLC, a privately held company based in Plano, Tex., sells travel club memberships providing a diverse set of lifestyle products and experiences. The company's goal is to help Independent Representatives, DreamTrips™ Members and employees achieve more fun, freedom and fulfillment in their lives. WorldVentures uses the direct sales model to go to market with active Representatives and Members in 29 countries. For more information, visit www.worldventures.com.

About WorldVentures Foundation

The WorldVentures Foundation is a 501(c)3 organization with a mission to create positive change in the lives of children all over the world. The Foundation supports sustainable programs that promote children's health, happiness, safety and development. Represented by the Heart to Serve logo and tagline, the mission is accomplished through four main ways: VolunTours, Volunteer Days, DreamCourts™ and fundraising. Learn more at www.worldventuresfoundation.org.

About NXT-ID, Inc.—Mobile Security for a Mobile World

NXT-ID, Inc.'s (NASDAQ:NXTD) (NXTDW) innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio® suite of solutions that secure consumers' mobile platforms. For more information, please visit www.nxt-id.com.

Media contact:

Connie Glover
Public Relations Manager
WorldVentures Holdings, LLC
o: 972.805.9600 ext. 2521 c: 214.726.2567
press@worldventures.com

NXT- ID Inc Contact:

Corporate info: info@nxt-id.com

Media:

D. Van Zant

800 665-0411

press@nxt-id.com

Visit this company: nxt-id.com; 3d-id.net; wocketwallet.com/

More info on NXTD at Investorideas.com Visit: http://www.investorideas.com/CO/NXT/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of October 1, 2015 NXT-Id renewed for one year –five thousand per month and fifteen thousand 144 restricted shares for PR, media and marketing. http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp

#Technology, #Mining #Stocks and #FoodSciences/#Hemp Company #LexariaBioscience Corp. (CSE: $LXX; OTC: $LXRP) Added to Investorideas.com

#Technology, #Mining #Stocks and #FoodSciences/#Hemp Company #LexariaBioscience Corp. (CSE: $LXX; OTC: $LXRP) Added to Investorideas.com

Technology Stock Additions Include: TSX Venture: $CTZ.V, $ES.V, $ILA.V, $INT.V, $INX.V, $IVI.V, $MCC.V, $OEE.V, $RHT.V, $QHR.V, $QIS.V, $RW.V, $RSY.V, $SCG.V, $SEB.V, $SPZ.V, $SYZ.V, $SY.V, $SYN.V, $MIT.V, $TTZ.V, $VPY.V, $VV.V, $VQS.V, $VIS.V and $ZAO.V

Point Roberts, WA, Delta BC – July 15, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories.  Additions are within the technology and mining sectors, with a focus on TSX Venture Exchange Traded Technology Stocks.

New Mining companies are TSX, TSX Venture, Nasdaq, Canadian Stock Exchange and NYSE Listed companies and include focuses on mining in Mexico, Peru, Turkey, Canada and the US.

Also added is food science company, Lexaria Bioscience Corp. (CSE:LXX; OTC:LXRP), whose food products include Vipova™ - a hemp oil infused black tea and Lexaria Energy Bar – a hemp-infused energy bar.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Read this release in full at http://www.investorideas.com/news/2016/technology/07151.asp

Tech Companies Added:

Cencotech Inc (TSX:CTZ.V), Eight Solutions Inc. (TSX:ES.V), iLOOKABOUT Corp (TSX:ILA.V), Intertainment Media Inc (TSX:INT.V), In-Touch Survey Systems Ltd (TSX:INX.V), Ivrnet Inc (TSX:IVI.V), Magor Corporation (TSX:MCC.V), Memex Inc (TSX:OEE.V), Reliq Health Technologies Inc. (TSX:RHT.V), QHR Technologies Inc. (TSX:QHR.V), Quorum Information Technologies Inc (TSX:QIS.V), RenoWorks Software Inc (TSX:RW.V), RSI International Systems Inc (TSX:RSY.V), Selectcore Ltd (TSX:SCG.V), Smart Employee Benefits Inc. (TSX:SEB.V), Spriza Media Inc. (TSX:SPZ.V), Sylogist Ltd (TSX:SYZ.V), Symbility Solutions Inc (TSX:SY.V), Syncordia Technologies and Healthcare Solutions, Corp. (TSX:SYN.V),  Mint Technology Corp., The (TSX:MIT.V), Total Telcom Inc (TSX:TTZ.V), VersaPay Corp (TSX:VPY.V), Versatile Systems Inc (TSX:VV.V), VIQ Solutions Inc (TSX:VQS.V), Visionstate Corp. (TSX:VIS.V) and Zaio Corporation (TSX:ZAO.V)

Mining Companies Added:

Peruvian Precious Metals Corp. (TSX:PPX.V), Pele Mountain Resources Inc. (TSX:GEM.V), Palamina Corp. (TSX:PA.V), Pasinex Resources Ltd. (CSE:PSE), Pershing Gold Corp. (NasdaqGM:PGLC), Pilot Gold Inc. (TSX:PLG.TO), Pretium Resources Inc. (NYSE: PVG; TSX:PVG.TO) and Pure Gold Mining Inc. (TSX:PGM.V)

Food Science/Hemp Company:

Lexaria Bioscience Corp. (CSE:LXX; OTC:LXRP) is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies. Lexaria’s technology enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria hopes to reduce other common but less healthy ingestion methods such as smoking as it embraces the benefits of public health.

About Investorideas.com - News that Inspires Big Ideas

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

#China XD Plastics Company (NASDAQ: $CXDC) Makes NASDAQ Top Percentage Gainer List

#China XD Plastics Company (NASDAQ: $CXDC) Makes NASDAQ Top Percentage Gainer List

#China #Stocks in Play Again?....

Point Roberts, WA, Delta BC – July 13 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors reports on NASDAQ gainer, China XD Plastics Company Ltd. (NASDAQ: CXDC). The stock is trading at $4.53,  up 0.76 (20.16 %), making it the second top gainer on NASDAQ today.

The Company, one of China's specialty chemical companies engaged in the development, manufacture and sale of polymer composite materials primarily for automotive applications, announced last week  that it held a commissioning ceremony on July 7, 2016 at its new Sichuan manufacturing facility.

The press release stated-"We are grateful for the tremendous support from the Nanchong municipal and Shunqing district authorities as our new production facility in Sichuan Province was completed in a little over a year since the company broke ground," said Jie Han, Chairman of the Board of Directors and Chief Executive Officer. "The commissioning ceremony featured our new, high-tech facility which is fully automated, and plant tours showcased the culmination of the cooperative efforts between our project development team and officials in the region and many partners who understand the evolution of China's Southwest region into a major high-tech and transportation manufacturing center to include automobiles, high-speed rail, shipping and aviation. With over 700 participants, we were able to showcase how our Sichuan campus will diversify our product platform into additional high-growth verticals such as advanced transportation, bio-degradable materials, medical-grade materials and food packaging."

China XD Plastics Company Limited, through its wholly-owned subsidiaries, develops, manufactures and sells polymer composites materials, primarily for automotive applications. The Company's products are used in the exterior and interior trim and in the functional components of 28 automobile brands manufactured in China, including without limitation, Audi, Mercedes Benz, BMW, Buick, Chevrolet, VW Passat, Golf and Jetta, Mazda, and Toyota. The Company's wholly-owned research center is dedicated to the research and development of polymer composites materials and benefits from its cooperation with well-known scientists from prestigious universities in China. As of March 31, 2016, 369 of the Company's products have been certified for use by one or more of the automobile manufacturers in China. For more information, please visit the Company's English website at http://www.chinaxd.net, and the Chinese website at http://www.xdholding.com.

Read this release in full at http://www.investorideas.com/news/2016/china/07131.asp

About Investorideas.com - News that Inspires Big Ideas

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

#Biopharma News: Eleven Biotherapeutics (NASDAQ: $EBIO) Announces Effectiveness of Investigational New Drug Application for EBI-031

#Biopharma News: Eleven Biotherapeutics (NASDAQ: $EBIO) Announces Effectiveness of Investigational New Drug Application for EBI-031

Eleven entitled to receive $22.5 million milestone payment for IND effectiveness

CAMBRIDGE, Mass. - July 8, 2016 (Investorideas.com Newswire) Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that the company's Investigational New Drug (IND) application for EBI-031, a humanized monoclonal antibody that potently binds interleukin-6 (IL-6) and inhibits all known forms of IL-6 cytokine signaling, for treatment of ocular diseases, has become effective. As a result of the achievement of this milestone, Eleven is entitled to receive a $22.5 million payment from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) pursuant to the terms of its license agreement with Roche.

On June 13, 2016, Eleven announced that it had entered into an exclusive license agreement with Roche for the further development and commercialization of EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven. Under the terms of the agreement, Eleven could receive up to $262.5 million upon the achievement of certain regulatory, development and commercialization milestones, including this $22.5 million payment upon the effectiveness of the IND for EBI-031. In addition, Eleven could be entitled to receive royalties for net sales of potential future products containing EBI-031 or any other potential future products containing other Eleven IL-6 compounds. Effectiveness of the license agreement, including Roche's obligation to make the $22.5 million milestone payment, is subject to approval of the license by holders of at least a majority of the outstanding shares of Eleven's common stock.

"We look forward to Roche advancing EBI-031 into the clinic to explore its potential use for ocular diseases, such as diabetic macular edema, in an effort to bring this potential treatment to patients," said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics.

Read this release in full at http://www.investorideas.com/news/2016/biotech/07081.asp

About EBI-031

Eleven Biotherapeutics' most advanced preclinical product candidate is EBI-031 for treatment of diabetic macular edema, or DME, and uveitis. EBI-031 was designed and engineered for intravitreal delivery using Eleven's AMP-Rx platform. EBI-031 is a potent blocker of both free IL-6 and IL-6 complexed to the soluble IL-6 receptor (IL-6R). Eleven filed an IND with the FDA in June 2016 for the purpose of conducting clinical trials of EBI-031 in DME and uveitis.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven's therapeutic approach is based on the role of cytokines in diseases of the eye, the Company's understanding of the structural biology of cytokines and the Company's ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.

For more information please refer to the Company's website www.elevenbio.com.

Important Information

The Company plans to file with the Securities and Exchange Commission ("SEC") and mail to its stockholders a proxy statement in connection with the transactions contemplated by the license agreement. Additionally, the Company will file other relevant materials with the SEC in connection with the transactions contemplated by the license agreement. The proxy statement will contain important information about the Company, the transactions contemplated by the license agreement and related matters. Investors and security holders are urged to read the proxy statement carefully when it is available before making any voting or investment decision with respect to the proposed transactions because they will contain important information about the proposed transactions.

Investors and security holders will be able to obtain free copies of the proxy statement and other documents filed with the SEC by the Company through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of the proxy statement from public company by contacting Leah Monteiro at (617) 714-0619.

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the license agreement. Information regarding the Company's directors and executive officers is contained in the Company's Form 10-K for the fiscal year ended December 31, 2015, and its proxy statement dated April 29, 2016, each of which has been filed with the SEC. Additional information regarding the participants in the solicitation of proxies in respect of the transactions contemplated by the license agreement and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the potential effectiveness of the license agreement or receipt of payments thereunder, the future rights and obligations of the parties under the license agreement, the Company's strategy, future operations, advancement or maturation of its product candidates and product pipeline, clinical development of the Company's product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical trials and registration of product candidates, the review of its strategic alternatives and the outcome of such review, the completion and results of potential strategic transactions, the sufficiency of its cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the occurrence of any event, change or other circumstances that could give rise to the termination of the license agreement, the outcome of any legal proceedings that could be instituted against the Company or its directors related to the license agreement, the inability to consummate the transactions contemplated by the license agreement due to the failure to obtain the requisite approval of the Company's stockholders, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, the adequacy of any clinical models, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals and other factors discussed in the "Risk Factors" section of the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2016 as filed with the Securities and Exchange Commission and other reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Source: Eleven Biotherapeutics, Inc.

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info

http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info

http://www.bcsc.bc.ca/release.aspx?id=6894.

Global investors must adhere to regulations of each country.

#InvestorIdeas Adds #Technology and #Biotech #Stocks ($INSY, $CTBO and $EBIO) to Directories

#InvestorIdeas Adds #Technology and #Biotech #Stocks ($INSY, $CTBO and $EBIO) to Directories

Technology Stock Additions Include: TSX Venture: $AKR.V, $BPL.V, $MKT.V, $EQ.V, $FSW.V, $KBY.V, $AT.V, $BKD.V, $BTL.V, $DXX.V, $MVP.V, $MBO.V, $MV.V, $PGV.V, $PFM.V

Point Roberts, WA, Delta BC – July 8, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories.  Additions are mainly within the technology sector, with a focus on TSX Venture Exchange Traded Stocks.

Also added are three biotech companies -  INSYS Therapeutics, Inc. (NasdaqGM: INSY) focused on novel drug delivery systems and treating addiction to opioids, opioid overdose and epilepsy; Cantabio Pharmaceuticals Inc. (OTC:CTBO)  which is focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s, Parkinson’s and oxidative stress; and Eleven Biotherapeutics, Inc. (NasdaqGM:EBIO) which focuses on the discovery and development of protein therapeutics to treat diseases of the eye.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Read this release in full at http://www.investorideas.com/news/2016/main/07082.asp

Tech Companies Added: Ackroo Inc. (TSX:AKR.V), Bluedrop Performance Learning Inc (TSX:BPL.V), DeepMarkit Corp. (TSX:MKT.V), EQ Inc. (TSX:EQ.V), Fireswirl Technologies Inc (TSX:FSW.V), Kona Bay Technologies Inc. (TSX:KBY.V), AcuityAds Holdings Inc (TSX: AT.V), Breaking Data Corp. (TSX:BKD.V), BTL Group Ltd (TSX:BTL.V), DXStorm.com Inc (TSX:DXX.V), MediaValet Inc (TSX:MVP.V), Mobio Technologies Inc. (TSX:MBO.V), MOVIT Media Corp. (TSX:MV.V), Prodigy Ventures Inc (TSX:PGV.V) and ProntoForms Corporation (TSX:PFM.V).

Biotech:

INSYS Therapeutics, Inc. (NasdaqGM: INSY) is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product, Subsys® (fentanyl sublingual spray) but has received approval for the marketing of Syndros™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy and other disease areas with high unmet need. Subsys® and Syndros™ are trademarks of Insys Therapeutics, Inc.

Cantabio Pharmaceuticals Inc. (OTC:CTBO) is focused on bringing novel, first in class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s and Parkinson’s, and oxidative stress.

Eleven Biotherapeutics, Inc. (NasdaqGM:EBIO) is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.

About Investorideas.com - News that Inspires Big Ideas

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Gopher Protocol (OTCQB:$GOPH) Announces Completion and Testing of Guardian Patch Prototypes

Gopher Protocol (OTCQB:$GOPH) Announces Completion and Testing of Guardian Patch Prototypes

SAN DIEGO, CA - July 7, 2016 (Investorideas.com Newswire) Gopher Protocol Inc. (OTCQB: GOPH) ("Gopher" and the "Company"), a development-stage Company which specializes in the development of real-time, heuristic based mobile technologies, and its partner, Guardian Patch LLC, announced today that they have completed the design and construction of the Guardian Patch circuit prototype device. The Company has completed the construction of 10 prototype units and is now proceeding with an intensive testing program.

The Guardian Patch prototypes are working with the Company's mobile app, which can be downloaded for free at the Apple Store and on Google Play under the name "Guardian Patch." As a courtesy to the public, the Company previously released the Guardian Patch app to provide users with live views of the Guardian Patch units during testing.

The Guardian Patch prototype unit contains the Company's GOPHERINSIGHT™ integrated circuit technology (see image below). The Guardian Patch prototype consists of mobile units and base units. The base unit is programmed to report on each mobile unit's real-time position to a web-based computer program which analyzes the information and sends it through the internet to the mobile app. The end results is an accurate location and progress presentation of the Guardian Patch mobile unit on a mobile map.

The prototype system is currently reporting about the mobile unit's location every few seconds in order to test a real-time positioning system. In this way, viewers may view live, real time movement of the tested mobile units on the app's map. The web-based program is also providing statistical information about the mobile units, including, but not limited to, travel distance, cities visited, travel time and more. This data will be used in the future to enhance customers' vital statistics for personal purposes. In addition, other electrical factors are measured and studied, such as electrical power consumption, transmission intervals, terrain and weather effects and more. In parallel, the Company is constantly enhancing and improving the system's software to handle large amount of mobile units and their coverage.

Special attention is also given to human engineering of user friendly UI (User Interface) of the mobile application software and the web-based control program. Additionally, a robust database management system is being designed in order to manage large number of mobile units efficiently.

The Guardian Patch prototype, which the Company hopes will arrive in the consumer markets sometime in 2017, of which there is no guarantee, is a unique location technology that works with or without GPS. It is a stick-on tracking device that protects and tracks objects, from a phone to a laptop to a loved one or a pet, through a mobile app.

Read this release in full at http://www.investorideas.com/CO/GOPH/news/2016/07071.asp

About Guardian Patch

The Guardian Patch (the "Patch"), potentially arriving in consumer markets in 2017, is a unique location technology that works with or without GPS. The Patch is a "stick-on" device that provides its users with the capability to protect and track objects, a loved-one or even a pet, through a mobile application. Download the Patch app, register your patch, and track anything that you own on your mobile device or on our designated website. Register the Patches of your family members and friends to receive alerts in the event of an emergency. Peel the Patch off and the Patch acts as a beacon, sending out a signal and notifying anyone who has registered the user's Patch.

About Gopher Protocol Inc.

Gopher Protocol Inc. (OTCQB: GOPH) ("Gopher" and the "Company") (http://gopherprotocol.com/) is a development-stage company developing a real-time, heuristic-based mobile technology. Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that will run on a server. The system contemplates the creation of a global network. Gopher believes this will be the first system that is developed using a human, heuristic-based analysis engine. Since the core of the system will be its advanced microchip technology that will be capable of being installed in any mobile device worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the microchip by providing mobile technology for computing power enhancement, advanced mobile database management/sharing and other additional mobile features.

Corporate Site: http://gopherprotocol.com

Press page/ press kit: http://gopherprotocol.com/?page_id=228

Consumer and product website for Guardian Patch: http://www.guardianpatch.com/.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:

Dr. Dan Rittman, CTO
Gopher Protocol Inc.
888-685-7336
Media: press@gopherprotocol.com

Visit this company: http://gopherprotocol.com/

More info on GOPH at Investorideas.com Visit: http://www.investorideas.com/CO/GOPH/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com ( three months effective April 4, 2016- three thousand five hundred per month )

More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.